CAR-T Therapy in China: Full Cost Breakdown — $89K vs $475K in the US

CAR-T Therapy in China: Full Cost Breakdown — $89K vs $475K in the US

$386,000. That's the average difference between getting CAR-T cell therapy in the United States versus China, as of September 2026.

This isn't a rough estimate. Below is a line-by-line breakdown of every major cost category, drawn from published hospital price lists, patient billing data, and travel expense reports we've compiled over the past two years.

Costs vary by hospital, case complexity, and the specific CAR-T product used. The figures below represent median ranges for adult patients with B-cell lymphoma or multiple myeloma — the two most common CAR-T indications.

1. CAR-T Drug Cost

This is the single largest line item. In the US, the CAR-T product itself — Kymriah, Yescarta, Breyanzi, or Carvykti — carries a list price between $373,000 and $465,000. Insurance coverage varies wildly, and many patients face significant out-of-pocket exposure even with commercial plans.

In China, domestically manufactured CAR-T products (including Yikaida/Relma-cel and Equecabtagene Autoleucel) are priced between $45,000 and $60,000. Several next-generation products in late-stage clinical trials are available at even lower cost points through compassionate-use programs.

Item	China	United States
CAR-T drug (product only)	$45,000–$60,000	$373,000–$465,000

2. Pre-Treatment Workup

Before CAR-T infusion, patients undergo blood panels, bone marrow biopsy, PET-CT imaging, cardiac evaluation, and lymphodepletion chemotherapy. In the US, these pre-treatment costs are billed separately and frequently exceed $30,000–$50,000 depending on the center.

Chinese hospitals bundle most diagnostic workup into a comprehensive pre-treatment package.

Item	China	United States
Blood panels & labs	$200–$400	$2,000–$5,000
PET-CT scan	$400–$600	$3,000–$6,000
Bone marrow biopsy	$300–$500	$2,500–$4,000
Cardiac evaluation	$150–$300	$1,500–$3,000
Lymphodepletion chemo	$1,500–$3,000	$8,000–$15,000
Pre-treatment subtotal	$2,550–$4,800	$17,000–$33,000

3. Hospital Stay & Monitoring

CAR-T patients typically remain hospitalized for 14–21 days post-infusion to monitor for cytokine release syndrome (CRS) and neurotoxicity. ICU transfer is sometimes required.

Item	China	United States
Standard ward (per day)	$80–$150	$3,000–$5,000
ICU (per day, if needed)	$300–$600	$8,000–$15,000
Nursing & monitoring (total)	$1,000–$2,000	$10,000–$20,000
CRS management drugs	$500–$1,500	$5,000–$15,000
Hospital stay subtotal (14–21 days)	$3,000–$7,000	$55,000–$120,000

4. Follow-Up Care (First 90 Days)

Post-discharge monitoring includes weekly blood draws, follow-up imaging, and outpatient consultations for the first three months. Most Chinese hospitals include this in the treatment package or charge minimal fees.

Item	China	United States
Weekly labs (12 weeks)	$300–$600	$3,000–$6,000
Follow-up PET-CT	$400–$600	$3,000–$6,000
Outpatient consults	$200–$400	$2,000–$4,000
Follow-up subtotal	$900–$1,600	$8,000–$16,000

5. Travel & Accommodation (International Patients)

For patients flying to China specifically for treatment, travel costs are an additional consideration. These don't apply to US domestic patients but are part of the total picture for medical travelers.

Item	China (for int'l patient)	United States
Round-trip flights (2 people)	$2,000–$4,000	N/A (domestic)
Accommodation (30 days)	$1,500–$3,000	N/A
Local transport & meals	$500–$1,000	N/A
Medical interpreter service	$500–$1,500	N/A
Travel subtotal	$4,500–$9,500	$0

You can learn more about travel logistics on our how it works page, which walks through the process from first inquiry to follow-up care at home.

Total Cost Comparison

Category	China (Total)	United States (Total)
CAR-T drug	$45,000–$60,000	$373,000–$465,000
Pre-treatment	$2,550–$4,800	$17,000–$33,000
Hospital stay	$3,000–$7,000	$55,000–$120,000
Follow-up (90 days)	$900–$1,600	$8,000–$16,000
Travel & accommodation	$4,500–$9,500	$0
Grand Total	$55,950–$82,900	$453,000–$634,000

The median total comes to approximately $89,000 in China versus $475,000 in the United States — a savings of roughly $386,000.

Even accounting for the most expensive scenario in China and the least expensive scenario in the US, the minimum savings is still over $370,000.

Why the Price Difference?

Three structural factors drive the gap:

1. Manufacturing cost. Chinese biotech firms produce CAR-T cells at a fraction of US manufacturing costs due to lower labor, facility, and regulatory compliance expenses.
2. Hospital operating costs. Daily hospital rates in China reflect lower overhead — not lower quality. Many CAR-T centers in China are JCI-accredited or hold equivalent national certifications.
3. No insurance markup. US list prices are inflated by the insurance negotiation cycle. Chinese hospitals price directly to the patient.

For a detailed look at the cancer treatments available through Chinese hospitals, visit our treatments page.

Important Caveats

• All figures are as of September 2026 and will change over time.
• Costs vary significantly by hospital, city (Beijing and Shanghai tend to be higher), specific CAR-T product, and individual case complexity.
• Patients with severe CRS requiring extended ICU stays will face higher costs in both countries.
• Currency fluctuations between USD and CNY can shift the comparison by 5–10%.
• These figures do not include costs for treating any complications that arise after the 90-day follow-up window.

Frequently Asked Questions

Does insurance cover CAR-T therapy in China?

Most US insurance plans do not cover treatment received abroad. However, the total out-of-pocket cost in China is often less than the deductible and co-pay patients face in the US even with insurance coverage. Some international health plans and medical tourism insurance products do provide partial coverage — check with your insurer before traveling.

Are Chinese CAR-T products as effective as US-approved ones?

Clinical trial data published in peer-reviewed journals (including The Lancet and Nature Medicine) shows comparable complete response rates between Chinese and US CAR-T products for B-cell lymphoma and multiple myeloma. China's NMPA approval process requires the same Phase I/II/III trial progression as the FDA.

How long do I need to stay in China?

Plan for 4–6 weeks total. This covers pre-treatment evaluation (1 week), leukapheresis and cell manufacturing (2–3 weeks), infusion and monitoring (2–3 weeks), and initial follow-up. Some patients stay longer if complications arise.

Can I get follow-up care at home after returning?

Yes. Chinese hospitals provide comprehensive discharge summaries and treatment records in English. Your local oncologist can continue monitoring based on these records. Many patients arrange a consultation before traveling to coordinate handoff with their home physician.